Topamax Articles
Tentative FDA approval for Supernus' Trokendi XR
27 June 2012
Topiramate carries risk of birth defect, says US FDA
7 March 2011
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
Johnson & Johnson to shed 6%-7% of jobs; confirms 2009 guidance
4 November 2009
Johnson & Johnson’s 3rd quarter disappoints, as generics gouge leading drugs, though cost cuts help profits
14 October 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
Teva to launch generic Topamax in USA
31 March 2009
Stock Commentary - New York week to March 23, 2009
30 March 2009
Zydus gains final approval of generic Topamax
30 March 2009
Anti-epileptics to get suicide warnings in USA
22 December 2008
Stock Commentary - New York week to July 7, 2008
14 July 2008
Stock Commentary - New York week to May 26, 2008
2 June 2008
J&J's 4th-qtr 2007 sales jump 16.6%, EPS up 11%
28 January 2008
Patent expiry for 2008 provides generic opportunity
14 January 2008
UPDATE: 2007 NASSO conference hears encouraging data on GSK's alli, Orexigen's Contrave et al
29 October 2007
Vivus' Qnexa boosts QoL in obese patients
29 October 2007
Charges hit J&J's third qtr; forecast raised
22 October 2007
J&J's Topamax may help alcoholics quit
15 October 2007
Nine NCEs added to Japan's NHI drug list
8 October 2007
Japan stock market week to September 24, 2007
1 October 2007
Tentative FDA OK for Mylan's topiramate
17 September 2007
Stock Commentary - New York week to August 6, 2007
13 August 2007
Stock Commentary - New York week to July 23, 2007
30 July 2007
J&J's 2nd-qtr 2007 net income jumps 9.2%
23 July 2007
Japanese regulator gives nod to three new drugs
21 May 2007
J&J's 1st-qtr profits slip 22% on Conor buy
23 April 2007
J&J subsids receive three US subpoenas
19 March 2007
J&J's 4th qtr 2006 EPS beats analysts' estimate
29 January 2007
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Vivus raises $33.6 million
27 November 2006
Stock Commentary - New York week to Nov 6, 2006
13 November 2006
J&Js 3rd-qtr profit rises 8.7% to $2.76B
23 October 2006
J&J's record 2nd-qtr 2006 sales boost profit 10%
24 July 2006
Stock Commentary - New York week to July 10, 2006
17 July 2006
Stock Commentary - New York week to May 15, 2006
22 May 2006
Vivus' Onexa performs well in obesity study
15 May 2006
Tentative OK for Teva's generic topiramate 50mg
13 March 2006
J&J's 4th-qtr 2005 sales drop 1.1% on low Rx
30 January 2006
J&J's 4th-qtr net earnings plunge 34%
31 January 2005
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
UK for J&J's epilepsy drug Topamax in migraine
23 August 2004
Tokyo pharma stocks - week to August 16
23 August 2004
UK NICE guidance on insomnia drugs
10 May 2004
J&J's sales leap 17.7% for 1st-qtr 2004
19 April 2004
Pfizer continues to dominate neurology drug market
29 March 2004
UK NICE backs newer antiepileptics
29 March 2004
J&J 4th-qtr EPS up 35%, sales rise 20%
26 January 2004
J&J gets TransForm's topiramate patent
22 December 2003
J&J on track for new use of Topamax
24 November 2003
US media probe finds soaring off-label Rx use
10 November 2003
J&J raises forecast on strong 3rd quarter
20 October 2003
Janssen-Cilag's topiramate expected to grow migraine prevention market
29 September 2003
New data for UCB Pharma's Keppra
15 September 2003
Acquisition charges hit J&J 2nd-qtr results
21 July 2003
J&J files Topamax for migraine prevention
6 January 2003
J&J
22 July 2002
J&J earnings climb 18.2% in 1st qtr
22 April 2002
J&J halts Topamax obesity trials
11 February 2002
J&J posts healthy increase in sales and earnings for 2001
28 January 2002
Topamax may have role in bipolar disorder
6 December 2001
J&J warns of eye disorder with Topamax
17 September 2001
FDA backs Ortho-McNeil' s Topamax again
6 September 2001
J&J to develop Topamax as weight-loss drug
31 May 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
Euro epilepsy drug sales "to grow 17.2%/year"
19 February 2001
Parkinson's market "may double by 2008"
22 February 2000
New pediatric indication for Topamax
27 July 1999
Epilepsy Market Sees Strong Growth
29 July 1997
Canada Clears Janssen-Ortho's Topamax
26 March 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
FDA Year-End Approval Spate As Expected
6 January 1997
Continued Approval Of Blockbuster Products In '97?
23 December 1996
UK Industry Code of Practice Review
8 July 1996
NCEs In 1995: A Good Range Of Novel Drugs
29 January 1996
First World Launch Of Janssen-Cilag's Topamax
9 October 1995
Showing 1-95 of 95 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
